

Customer Circular

30 January 2025

Supply Information: Q-VAX® Vaccine (10041788) & Q-VAX® Skin Test (10040156) (inactivated *Coxiella burnetii*)

Dear Valued Customer,

CSL Seqirus is pleased to inform you that stock for Q-VAX® Vaccine & Q-VAX® Skin Test is anticipated to be available across all states commencing the week of 4th February 2025.

Please note that all orders for Q-VAX® Vaccine & Q-VAX® Skin Test will continue to be assessed daily and supply will continue to be manually allocated for the short term. This may result in a potential short delay in delivery as CSL Seqirus works to ensure stock availability for all patients.

Q-VAX® Vaccine & Q-VAX® Skin Test product information is available at www.cslseqirus.com.au/products or please contact CSL Seqirus Medical Information. If you have any queries, or would like further information, please do not hesitate to contact our customer service team at:

Medical Information – 1800 642 865
aunz.medicalinformation@seqirus.com

Customer Service – 1800 008 275
customer.service.au@seqirus.com

We appreciate your patience and support throughout this time.

Yours sincerely,



Emmy Said
Senior Brand Manager – Products of National Significance

If you do not wish to receive further information about any CSL Seqirus products and services, please email SeqirusAU.SalesSupport@seqirus.com or provide your fax number here: _____ and fax back to (03) 9389 2030. Before prescribing, please review the Product Information at www.cslseqirus.com.au/products. Seqirus Medical Information: 1800 642 865.